# US 2017/0362211 A1 · Small molecule inhibitors of fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362211 A1
- Document ID: US20170362211A1
- Status: Published application
- Kind: A1
- Application number: 15/534,225
- Filed: 2015-12-09
- Published: 2017-12-21
- Earliest claimed: 2014-12-10
- Assignees: The California Institute for Biomedical Research; The Scripps Research Institute
- Applicants: The California Institute for Biomedical Research; The Scripps Research Institute
- Inventors: Luke LAIRSON; Arnab K. CHATTERJEE; Michael BOLLONG; Baiyuan YANG; Peter G. SCHULTZ
- Web page: https://patentgrep.com/patent/US20170362211A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 495/04: Ortho-condensed systems
- A01N 57/00: Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

## Abstract

Described herein are compounds and compositions for the treatment of a fibrotic disease.

## Claims

### Claim 1

A compound of Formula (I) having the structure:
wherein:
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached; and
n is selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 2

A compound of Formula (Ia) having the structure:
wherein:
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), -alkylene(heterocycloalkyl), or
R2 is alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached; and
n is selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein R1 is -alkylene(cycloalkyl).

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is —CH2-(cycloalkyl).

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is —CH2-(cyclopentyl).

### Claim 6 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein R1 is —CH(CH2CH3)2.

### Claim 7 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein R1 is —CH(CH3)CH2CH2R2.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R2 is —CH3.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein n is 0.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein n is 1.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R8 is halogen, —CN, alkyl, alkoxy, haloalkoxy, or haloalkyl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein n is 2.

### Claim 13 (depends on 12)

The compound of claim 12, wherein each R8 is independently selected from halogen, —CN, alkyl, alkoxy, haloalkoxy, and haloalkyl.

### Claim 14 (depends on 13)

The compound of claim 13, wherein each R8 is halogen.

### Claim 15 (depends on 14)

The compound of claim 14, wherein each R8 is Cl.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1-15, wherein R5 is H.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1-15, wherein R5 is halogen.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R5 is F.

### Claim 19 (depends on 1)

The compound of claim 1 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 20 (depends on 2)

The compound of claim 2 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 21

A compound of Formula (II) having the structure:
wherein:
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
each R7 is independently selected from halogen and alkyl;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
n is selected from 0, 1, 2, 3, and 4; and
m is selected from 0, 1, and 2;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 22

A compound of Formula (IIa) having the structure:
wherein:
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
each R7 is independently selected from halogen and alkyl;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
n is selected from 0, 1, 2, 3, and 4; and
m is selected from 0, 1, and 2;
or a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, deuteride, N-oxide, stereoisomer, or isomer thereof.

### Claim 23 (depends on 21, 22)

The compound of claim 21 or claim 22, wherein R4 is —CH3.

### Claim 24 (depends on 21, 22)

The compound of claim 21 or claim 22, wherein R4 is

### Claim 25 (depends on 21, 22)

The compound of claim 21 or claim 22, wherein R4 is

### Claim 26 (depends on 21, 22, 23, 24, 25)

The compound of any one of claims 21-25, wherein R1 is —CH(CH2CH3)2.

### Claim 27 (depends on 21, 22, 23, 24, 25)

The compound of any one of claims 21-25, wherein R1 is —CH(CH3)CH2CH2R2.

### Claim 28 (depends on 27)

The compound of claim 27, wherein R2 is H.

### Claim 29 (depends on 27)

The compound of claim 27, wherein R2 is —CH3.

### Claim 30 (depends on 21)

The compound of claim 21 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 31

A compound of Formula (III) having the structure:
wherein:
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
each R5 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
each R6 is independently selected from halogen, alkyl, and haloalkyl;
each R7 is independently selected from halogen, alkyl, haloalkyl, and —CN;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
n is selected from 0, 1, 2, 3, and 4;
p is selected from 0, 1, 2, 3, and 4;
q is selected from 0, 1, 2, 3, and 4; and
t is selected from 0, 1, 2, 3, and 4;
wherein at least one p, q, or t is not 0;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 32

A compound of Formula (IIIa) having the structure:
wherein:
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
each R5 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
each R6 is independently selected from halogen, alkyl, and haloalkyl;
each R7 is independently selected from halogen, alkyl, haloalkyl, and —CN;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
n is selected from 0, 1, 2, 3, and 4;
p is selected from 0, 1, 2, 3, and 4;
q is selected from 0, 1, 2, 3, and 4; and
t is selected from 0, 1, 2, 3, and 4;
wherein at least one p, q, or t is not 0;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 33 (depends on 31, 32)

The compound of claim 31 or claim 32, wherein each R5 is independently selected from —CH2NH2, —CF3, and —SO2Me.

### Claim 34 (depends on 31, 32, 33)

The compound of any one of claims 31-33, wherein p is 1.

### Claim 35 (depends on 31, 32, 33, 34)

The compound of any one of claims 31-34, wherein q is 0.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The compound of any one of claims 31-35, wherein t is 0.

### Claim 37 (depends on 31, 32)

The compound of claim 31 or claim 32, wherein q is 1.

### Claim 38 (depends on 37)

The compound of claim 37, wherein R6 is alkyl.

### Claim 39 (depends on 37, 38)

The compound of claim 37 or claim 38, wherein t is 0.

### Claim 40 (depends on 31, 32)

The compound of claim 31 or claim 32, wherein t is 1.

### Claim 41 (depends on 40)

The compound of claim 40, wherein R7 is halogen.

### Claim 42 (depends on 40, 41)

The compound of claim 40 or claim 41, wherein q is 0.

### Claim 43 (depends on 37, 38, 39, 40, 41, 42)

The compound of any one of claims 37-42, wherein p is 0.

### Claim 44 (depends on 31)

The compound of claim 31 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 45

A compound of Formula (IV) having the structure:
wherein:
R1 is
—CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
R5 and R6 are independently selected from H, alkyl, halo, and haloalkyl;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
R20 and R22 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14, wherein at least one of R20 and R22 is not F or Cl;
each R21 is independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; and
R23 is H;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 46

A compound of Formula (IVa) having the structure:
wherein:
R1 is
—CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
R5 and R6 are independently selected from H, alkyl, halo, and haloalkyl;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
R20 and R22 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14, wherein at least one of R20 and R22 is not F or Cl;
each R21 is independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; and
R23 is H;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 47

A compound of Formula (IVb) having the structure:
wherein:
R1 is
—CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
R5 and R6 are independently selected from H, alkyl, halo, and haloalkyl;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
R20 and R22 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14, wherein at least one of R20 and R22 is not F or Cl;
each R21 is independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; and
R23 is H;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 48 (depends on 45, 46, 47)

The compound of any one of claims 45-47, wherein R20 and R22 are independently selected from H, halogen, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, —SO2R13, —SO2NR13R14, and —C(O)NR13R14; wherein at least one of R20 and R22 is not F or Cl.

### Claim 49 (depends on 48)

The compound of claim 48, wherein R20 and R22 are independently selected from H, Cl, —CN, —CH3, —OCH3, and —CF3; wherein at least one of R20 and R22 is not Cl.

### Claim 50 (depends on 45, 46, 47, 48, 49)

The compound of any one of claims 45-49, wherein each R21 is independently selected from H, halogen, —CN, alkyl, alkoxy, and haloalkyl.

### Claim 51 (depends on 50)

The compound of claim 50, wherein each R21 is independently selected from H, Cl, —CN, —CH3, —OCH3, and —CF3.

### Claim 52 (depends on 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 45-51, wherein R4 is

### Claim 53 (depends on 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 45-51, wherein R4 is

### Claim 54 (depends on 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 45-51, wherein R4 is

### Claim 55 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 45-54, wherein R1 is
and R2 is H.

### Claim 56 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 45-54, wherein R1 is
and R2 is H.

### Claim 57 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 45-54, wherein R1 is
and R2 is H.

### Claim 58 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 45-54, wherein R1 is —CH(CH2CH3)2.

### Claim 59 (depends on 45)

The compound of claim 45 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 60 (depends on 46)

The compound of claim 46 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 61 (depends on 47)

The compound of claim 47 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 62

A compound of Formula (V) having the structure:
wherein:
R1 is
—CH(CH3)CH(R3)CH3, —CH(CH3)C(O)CH3, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R10 is H or alkyl;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
R20 is selected from H, Cl, Br, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
R21, R22, and R23 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; and
R24 is H;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 63

A compound of Formula (Va) having the structure:
wherein:
R1 is
—CH(CH3)CH(R3)CH3, —CH(CH3)C(O)CH3, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R10 is H or alkyl;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
R20 is selected from H, Cl, Br, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
R21, R22, and R23 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; and
R24 is H;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 64 (depends on 62, 63)

The compound of claim 62 or claim 63, wherein R21, R22, and R23 are independently selected from H, halogen, —CN, alkyl, alkoxy, and haloalkyl.

### Claim 65 (depends on 64)

The compound of claim 64, wherein R21, R22, and R23 are independently selected from H and halogen.

### Claim 66 (depends on 62, 63, 64, 65)

The compound of any one of claims 62-65, wherein R20 is independently selected from H, Cl, Br, —CN, alkyl, alkoxy, haloalkoxy, and haloalkyl.

### Claim 67 (depends on 66)

The compound of claim 66, R20 is independently selected from H, and Cl.

### Claim 68 (depends on 62)

The compound of claim 62 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 69

A compound of Formula (VI) having the structure:
wherein:
R is
R2 is H;
R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached; and
n is selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 70

A compound of Formula (VIa) having the structure:
wherein:
R1 is
R2 is H;
R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached; and
n is selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 71

A compound of Formula (VIb) having the structure:
wherein:
R1 is
R2 is H;
R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached; and
n is selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 72

A compound of Formula (VIc) having the structure:
wherein:
R1 is
R2 is H;
R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached; and
n is selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 73 (depends on 69, 70, 71, 72)

The compound of any one of claims 69-72, wherein n is 0.

### Claim 74 (depends on 69, 70, 71, 72)

The compound of any one of claims 69-72, wherein n is 1.

### Claim 75 (depends on 74)

The compound of claim 74, wherein R8 is halogen, —CN, alkyl, alkoxy, haloalkoxy, or haloalkyl.

### Claim 76 (depends on 69, 70, 71, 72)

The compound of any one of claims 69-72, wherein n is 2.

### Claim 77 (depends on 76)

The compound of claim 76, wherein each R8 is independently selected from halogen, —CN, alkyl, alkoxy, haloalkoxy, and haloalkyl.

### Claim 78 (depends on 77)

The compound of claim 77, wherein each R8 is halogen.

### Claim 79 (depends on 78)

The compound of claim 78, wherein each R8 is Cl.

### Claim 80 (depends on 69, 70, 71, 72)

The compound of any one of claims 69-72, wherein R5 is H.

### Claim 81 (depends on 69, 70, 71, 72)

The compound of any one of claims 69-72, wherein R5 is halogen.

### Claim 82 (depends on 81)

The compound of claim 81, wherein each R5 is F.

### Claim 83 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The compound of any one of claims 69-82, wherein R1 is

### Claim 84 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The compound of any one of claims 69-82, wherein R1 is

### Claim 85 (depends on 69)

The compound of claim 69 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 86 (depends on 70)

The compound of claim 70 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 87 (depends on 71)

The compound of claim 71 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 88 (depends on 72)

The compound of claim 72 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 89

A compound having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 90

A compound of Formula (IX) having the structure:
wherein:
—X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
Z1 is selected from O, S, NH, and NR13;
Z2 is selected from O, S, CH2, NH, and NR13;
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
each R7 is independently selected from halogen and alkyl;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
each R16 is independently selected from halogen, alkyl, and haloalkyl;
each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
n is selected from 0, 1, 2, 3, and 4;
m is selected from 0, 1, and 2;
p is selected from 0, 1, 2, 3, and 4;
q is selected from 0, 1, 2, 3, and 4; and
t is independently selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.

### Claim 91

A compound of Formula (IXa) having the structure:
wherein:
—X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
Z1 is selected from O, S, NH, and NR13;
Z2 is selected from O, S, CH2, NH, and NR13;
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
R4 is halogen, alkyl,
each R7 is independently selected from halogen and alkyl;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
each R16 is independently selected from halogen, alkyl, and haloalkyl;
each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
n is selected from 0, 1, 2, 3, and 4;
m is selected from 0, 1, and 2;
p is selected from 0, 1, 2, 3, and 4;
q is selected from 0, 1, 2, 3, and 4; and
t is independently selected from 0, 1, 2, 3, and 4;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.

### Claim 92 (depends on 90, 91)

The compound of claim 90 or claim 91, wherein R4 is

### Claim 93 (depends on 90, 91)

The compound of claim 90 or claim 91, wherein R4 is

### Claim 94 (depends on 90, 91)

The compound of claim 90 or claim 91, wherein R4 is

### Claim 95 (depends on 90, 91, 92, 93, 94)

The compound of any one of claims 90-94, wherein n is 0.

### Claim 96 (depends on 90, 91, 92, 93, 94)

The compound of any one of claims 90-94, wherein n is 1.

### Claim 97 (depends on 96)

The compound of claim 96, wherein R8 is halogen, —CN, alkyl, alkoxy, haloalkoxy, or haloalkyl.

### Claim 98 (depends on 90, 91, 92, 93, 94)

The compound of any one of claims 90-94, wherein n is 2.

### Claim 99 (depends on 98)

The compound of claim 98, wherein each R8 is independently selected from halogen, —CN, alkyl, alkoxy, haloalkoxy, and haloalkyl.

### Claim 100 (depends on 99)

The compound of claim 99, wherein each R8 is halogen.

### Claim 101 (depends on 100)

The compound of claim 100, wherein each R8 is F.

### Claim 102 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 90-101, wherein R1 is —CH(CH3)2.

### Claim 103 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 90-101, wherein R1 is —CH(CH2CH3)2.

### Claim 104 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 90-101, wherein R1 is

### Claim 105 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 90-101, wherein R1 is

### Claim 106 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 90-101, wherein R1 is

### Claim 107 (depends on 104, 105, 106)

The compound of any one of claims 104-106, wherein R2 is H.

### Claim 108 (depends on 104, 105, 106)

The compound of any one of claims 104-106, wherein R2 is —CH3.

### Claim 109 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The compound of any one of claims 90-108, wherein p is 0.

### Claim 110 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The compound of any one of claims 90-109, wherein q is 0.

### Claim 111 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The compound of any one of claims 90-110, wherein t is 0.

### Claim 112 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The compound of any one of claims 90-111, wherein Z1 and Z2 are each O.

### Claim 113 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The compound of any one of claims 90-112, wherein —X—Y— is —CH2CH2—.

### Claim 114 (depends on 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The compound of any one of claims 90-112, wherein —X—Y— is —CH═N—.

### Claim 115 (depends on 90)

The compound of claim 90 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 116 (depends on 91)

The compound of claim 91 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 117

A compound of Formula (X) having the structure:
wherein:
—X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
Z1 is selected from O, S, NH, and NR13;
Z2 is selected from O, S, CH2, NH, and NR13;
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
each R16 is independently selected from halogen, alkyl, and haloalkyl;
each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
n is selected from 0, 1, 2, 3, and 4;
p is selected from 0, 1, 2, 3, and 4;
q is selected from 0, 1, 2, 3, and 4; and
t is independently selected from 0, 1, 2, 3, and 4;
wherein when Z1 and Z2 are both O then —X—Y— is —CH═CH—, —CH═N—, or —N═CH—;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.

### Claim 118

A compound of Formula (Xa) having the structure:
wherein:
—X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
Z1 is selected from O, S, NH, and NR13;
Z2 is selected from O, S, CH2, NH, and NR13;
R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
R2 is H, alkyl, or —NR13R14;
R3 is —OH, alkyl, or —NR13R14;
each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
each R16 is independently selected from halogen, alkyl, and haloalkyl;
each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
n is selected from 0, 1, 2, 3, and 4;
p is selected from 0, 1, 2, 3, and 4;
q is selected from 0, 1, 2, 3, and 4; and
t is independently selected from 0, 1, 2, 3, and 4;
wherein when Z1 and Z2 are both O then —X—Y— is —CH═CH—, —CH═N—, or —N═CH—;
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.

### Claim 119 (depends on 117, 118)

The compound of claim 117 or claim 118, wherein n is 0.

### Claim 120 (depends on 117, 118)

The compound of claim 117 or claim 118, wherein n is 1.

### Claim 121 (depends on 120)

The compound of claim 120, wherein R8 is halogen, —CN, alkyl, alkoxy, haloalkoxy, or haloalkyl.

### Claim 122 (depends on 117, 118)

The compound of claim 117 or claim 118, wherein n is 2.

### Claim 123 (depends on 122)

The compound of claim 122, wherein each R8 is independently selected from halogen, —CN, alkyl, alkoxy, haloalkoxy, and haloalkyl.

### Claim 124 (depends on 123)

The compound of claim 123, wherein each R8 is halogen.

### Claim 125 (depends on 124)

The compound of claim 124, wherein each R8 is F.

### Claim 126 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125)

The compound of any one of claims 117-125, wherein R1 is —CH(CH3)2.

### Claim 127 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125)

The compound of any one of claims 117-125, wherein R1 is —CH(CH2CH3)2.

### Claim 128 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125)

The compound of any one of claims 117-125, wherein R1 is

### Claim 129 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125)

The compound of any one of claims 117-125, wherein R1 is

### Claim 130 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125)

The compound of any one of claims 117-125, wherein R1 is

### Claim 131 (depends on 128, 129, 130)

The compound of any one of claims 128-130, wherein R2 is H.

### Claim 132 (depends on 128, 129, 130)

The compound of any one of claims 128-130, wherein R2 is —CH3.

### Claim 133 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132)

The compound of any one of claims 117-132, wherein p is 0.

### Claim 134 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The compound of any one of claims 117-133, wherein q is 0.

### Claim 135 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134)

The compound of any one of claims 117-134, wherein t is 0.

### Claim 136 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The compound of any one of claims 117-135, wherein Z1 and Z2 are each O.

### Claim 137 (depends on 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The compound of any one of claims 117-136, wherein —X—Y— is —CH═N—.

### Claim 138 (depends on 114)

The compound of claim 114 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 139 (depends on 115)

The compound of claim 115 having the structure:
or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 140 (depends on 1, 139)

A pharmaceutical composition comprising a compound of any one of claims 1-139, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof, and a pharmaceutically acceptable excipient.

### Claim 141 (depends on 1, 139)

A method of treating fibrosis, a disorder characterized by fibrosis, or a disorder characterized by fibrosis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-139, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.

### Claim 142

A method to treat fibrosis, a disorder characterized by fibrosis, or a disease characterized by fibrosis, the method comprising administering a composition comprising a therapeutically effective amount of a compound of Formula (XI), a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof:
wherein:
A1 and A2 are independently selected from aryl or heteroaryl;
B is
C is optionally substituted 5- or 6-membered heterocyclyl or optionally substituted 5- or 6-membered heteroaryl, wherein the heterocyclyl or the heteroaryl contains 1 to 4 nitrogen atoms;
D is aryl or heteroaryl;
E is aryl, heteroaryl, carbocyclyl, hetercyclyl, or alkyl;
each R1, R2, R3, and R4 is independently selected from H, alkyl, haloalkyl, or alkoxy;
X1 and X2 are independently selected from N and CR5;
R5 is H, OH, alkyl, or alkoxy;
each R6 is independently alkyl, haloalkyl, halo, alkoxy, -alkylene(NR13R14), or aryl;
each R8 is independently selected from alkyl, cycloalkyl, heterocyclyl, halo, hydroxy, nitrile, azido, nitro, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14; or two adjacent R8 form a heterocyclyl ring;
each R13 and R14 is independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl; or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
Y1 is selected from O, NH, and NR13;
Y2 is selected from O, CH2, NH, and NR13;
n is 1, 2, or 3;
m is 1 or 2;
p is 1, 2, 3, or 4;
q is 1, 2, or 3;
r is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
s is 0, 1, 2, 3, or 4;
t is 0, 1, 2, 3, or 4;
u is 0, 1, 2, 3, 4 or 5; and
v is 0, 1, 2, 3, or 4.

### Claim 143 (depends on 142)

The method of claim 142, wherein X1 and X2 are N.

### Claim 144 (depends on 142)

The method of claim 142, wherein X1 is CR5 and X2 is N.

### Claim 145 (depends on 142)

The method of claim 142, wherein X1 is N and X2 is CR5.

### Claim 146 (depends on 143, 144, 145)

The method of any one of claims 143-145, wherein q is 1 and r is 0.

### Claim 147 (depends on 142, 143, 144, 145, 146)

The method of any of one of claims 142-146, wherein A1 is aryl.

### Claim 148 (depends on 147)

The method of claim 147 wherein A1 is

### Claim 149 (depends on 142, 143, 144, 145, 146)

The method of any of one of claims 142-146, wherein A1 is heteroaryl.

### Claim 150 (depends on 142, 143, 144, 145, 146, 147, 148, 149)

The method of any of one of claims 142-149, wherein A2 is aryl.

### Claim 151 (depends on 150)

The method of claim 150, wherein A2 is

### Claim 152 (depends on 142, 143, 144, 145, 146, 147, 148, 149)

The method of any of one of claims 142-149, wherein A2 is heteroaryl.

### Claim 153 (depends on 152)

The method of claim 152, wherein A2 is pyridine, pyrazine, pyrimidine, pyridazine, or triazine.

### Claim 154 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The method of any one of claims 142-153, wherein C is
and R7 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), cycloalkyl, heterocyclyl, -alkylene(cycloalkyl), or -alkylene(heterocyclyl).

### Claim 155 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The method of any one of claims 142-153, wherein C is
and R7 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), cycloalkyl, heterocyclyl, -alkylene(cycloalkyl), or -alkylene(heterocyclyl).

### Claim 156 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method of any one of claims 142-155, wherein E is alkyl.

### Claim 157 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method of any one of claims 142-155, wherein E is cycloalkyl.

### Claim 158 (depends on 157)

The method of claim 157, wherein E is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 159 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method of any one of claims 142-155, wherein E is heterocyclyl.

### Claim 160 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method of any one of claims 142-155, wherein E is aryl.

### Claim 161 (depends on 160)

The method of claim 160, wherein E is
and u is 0, 1, 2, 3, 4, or 5.

### Claim 162 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method of any one of claims 142-155, wherein E is heteroaryl.

### Claim 163 (depends on 162)

The method of claim 162, wherein
E is selected from:
W1, W2, W3, W4, W5, W6, and W7 are independently selected from N and CR9;
Z1 is NR12, S, or O;
Z2 is N or CR9;
each R9 is independently selected from H, halogen, CN, NO2,
alkyl, —SR10, —OR10, —NR10R11,
NR10C(O)(alkyl), —NR10C(O)(cycloalkyl), —NR10C(O)(heterocycloalkyl), —NR10C(O)(aryl), —NR10C(O)(heteroaryl), —C(O)NR10R11, —C(O)NR10(cycloalkyl), —C(O)NR10(heterocycloalkyl), —C(O)NR10(aryl), —C(O)NR10(heteroaryl), —NR10C(O)NR10R11, —NR10C(O)NR11(cycloalkyl), —NR10C(O)NR11(heterocycloalkyl), —NR10C(O)NR11(aryl), —NR10C(O)NR11(heteroaryl), —NR10C(O)O(alkyl), —NR10C(O)O(cycloalkyl), —NR10C(O)O(heterocycloalkyl), —NR10C(O)O(aryl), —NR10C(O)O(heteroaryl), —NR10SO2(alkyl), —NR10SO2(cycloalkyl), —NR10SO2(heterocycloalkyl), —NR10SO2(aryl), —NR10SO2(heteroaryl), —SO2NR10R11, —SO2NR10(cycloalkyl), —SO2NR10(heterocycloalkyl), —SO2NR10(aryl), —SO2NR10(heteroaryl), haloalkyl, aryl, and heteroaryl;
each R10 and R11 is independently selected from H and alkyl; or R10 and R11 taken together form a heterocycle with the nitrogen to which they are attached; and
R12 is H, alkyl or haloalkyl.

### Claim 164 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

The method of any one of claims 142-163, wherein D is aryl.

### Claim 165 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

The method of any one of claims 142-163, wherein D is heteroaryl.

### Claim 166 (depends on 165)

The method of claim 165, wherein
D is selected from
W1, W2, W3, W4, and W5 are independently selected from N and CR9;
W6 is N or C; and
each R9 is independently selected from H, halogen, CN, NO2,
alkyl, —SR10, —OR10, —NR10R11,
NR10C(O)(alkyl), —NR10C(O)(cycloalkyl), —NR10C(O)(heterocycloalkyl), —NR10C(O)(aryl), —NR10C(O)(heteroaryl), —C(O)NR10R11, —C(O)NR10(cycloalkyl), —C(O)NR10(heterocycloalkyl), —C(O)NR10(aryl), —C(O)NR10(heteroaryl), —NR10C(O)NR10R11, —NR10C(O)NR11(cycloalkyl), —NR10C(O)NR11(heterocycloalkyl), —NR10C(O)NR11(aryl), —NR10C(O)NR11(heteroaryl), —NR10C(O)O(alkyl), —NR10C(O)O(cycloalkyl), —NR10C(O)O(heterocycloalkyl), —NR10C(O)O(aryl), —NR10C(O)O(heteroaryl), —NR10SO2(alkyl), —NR10SO2(cycloalkyl), —NR10SO2(heterocycloalkyl), —NR10SO2(aryl), —NR10SO2(heteroaryl), —SO2NR10R11, —SO2NR10(cycloalkyl), —SO2NR10(heterocycloalkyl), —SO2NR10(aryl), —SO2NR10(heteroaryl), haloalkyl, aryl, and heteroaryl.

### Claim 167 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The method of any one of claims 142-166 wherein Y1 and Y2 are O.

### Claim 168 (depends on 167)

The method of claim 167 wherein m is 1.

### Claim 169 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168)

The method of any one of claims 142-168 wherein p is 1, 2, or 3.

### Claim 170 (depends on 169)

The method of claim 169 wherein p is 1.

### Claim 171 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170)

The method of any one of claims 142-170 wherein R1, R2, R3, and R4 are hydrogen.

### Claim 172 (depends on 142)

The method of claim 142 wherein the compound is:

### Claim 173 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The method of any one of claims 142-172 wherein the fibrosis is liver fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis, or cardiac fibrosis.

### Claim 174 (depends on 173)

The method of claim 173 wherein the liver fibrosis is associated with the later stages of alcoholic or nonalcoholic liver cirrhosis.

### Claim 175 (depends on 173)

The method of claim 173 wherein the fibrosis is idiopathic pulmonary fibrosis.

### Claim 176 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The method of any one of claims 142-172 wherein the disease characterized by fibrosis is a chronic autoimmune disease.

### Claim 177 (depends on 176)

The method of claim 176 wherein the chronic autoimmune disease is rheumatoid arthritis, scleroderma, Crohn's disease or systemic lupus erythematosus.

### Claim 178 (depends on 176)

The method of claim 176 wherein the chronic autoimmune disease is scleroderma.

### Claim 179 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The method of any one of claims 142-172 wherein the fibrosis is keloid formation resulting from abnormal wound healing.

### Claim 180 (depends on 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172)

The method of any one of claims 142-172 wherein the fibrosis occurs after organ transplantation.
